Biodefense / Pandemic Preparedness

The setup

The US government is significantly investing in biodefense and pandemic preparedness, with a strong focus on medical countermeasures. This effort is primarily driven by the Department of Health and Human Services (HHS) and the Department of Defense (DoD), who are issuing substantial contracts and solicitations for vaccines, antivirals, and integration services. The activity suggests a proactive stance on biological threats, building on existing frameworks and expanding capabilities.

How this developed

1. Dec 23, 2024The Beagle Brigade Act of 2023 was signed into law, formalizing USDA's National Detector Dog Training Center for agricultural biosecurity.Bill
2. Apr 30, 2026HHS's BARDA awarded Global Health Investment Corporation a $269.9M Other Transaction Agreement for BARDA Ventures.Federal contract
3. May 21, 2026HHS/ASPR/BARDA issued a Request for Information (RFI) for medical countermeasures against drug-resistant fungal infections.Procurement notice
4. Jun 2, 2026The Department of the Army issued a pre-solicitation for its BEACON Program, seeking Medical Countermeasure (MCM) Candidate Integration and Subcontractor Management.Procurement notice
5. Jun 26, 2026HHS/ASPR awarded Emergent Product Development Gaithersburg Inc. an $857.6M contract for ACAM2000 smallpox vaccine.Federal contract
6. Aug 24, 2026HHS/ASPR awarded SIGA Technologies, Inc. a $626.5M contract for procurement and late-stage development of smallpox antiviral drugs.Federal contract
7. Sep 10, 2026HHS/ASPR awarded Merck Sharp & Dohme LLC a $156M contract for ERVEBO (Ebola vaccine) procurement over 10 years.Federal contract
8. Sep 11, 2026HHS/ASPR/BARDA issued an RFP for vaccine medical countermeasures for pandemic influenza preparedness and response.Procurement notice

Why it matters

• HHS has committed over $1.48 billion to smallpox countermeasures (E9, E11), indicating a significant investment in preparing for a specific, high-consequence biological threat.
• The $156 million contract to Merck for Ebola vaccine (E12) demonstrates a long-term commitment to maintaining stockpiles and readiness against known viral threats.
• DoD's repeated pre-solicitations for the BEACON Program (E6, E7, E8) highlight an emphasis on integrating and managing medical countermeasure candidates, suggesting a focus on operationalizing new treatments.
• BARDA's RFI for drug-resistant fungal infections (E5) and RFP for pandemic influenza vaccines (E14) show a proactive approach to emerging and recurring infectious disease threats beyond traditional biodefense scenarios.

Named in a federal contract

Only companies that a specific contract in this theme names as recipient or parent. Not a recommendation.

The record · 10 items, oldest first

• Dec 23, 2024BillBeagle Brigade Act of 2023
• Apr 30, 2026Federal contractGLOBAL HEALTH INVESTMENT CORPORATION: OTHER TRANSACTION AGREEMENT: BARDA VENTURES
• May 21, 2026Procurement noticeRFI - Medical Countermeasures for the Treatment of Drug-Resistant Fungal Infections
• Jun 2, 2026Procurement noticeRPP: BEACON Program - Medical Countermeasure (MCM) Candidate Integration and Subcontractor Management
• Jun 3, 2026Procurement noticeRequest for Project Proposal (RPP): BEACON Program - Medical Countermeasure (MCM) Candidate Integration and Subcontractor Management
• Jun 11, 2026Procurement noticeRequest for Project Proposal (RPP): BEACON Program - Medical Countermeasure (MCM) Candidate Integration and Subcontractor Management
• Jun 26, 2026Federal contractEMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.: ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM)
• Aug 24, 2026Federal contractSIGA TECHNOLOGIES, INC.: PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF
• Sep 10, 2026Federal contractMERCK SHARP & DOHME LLC: $156M Department of Health and Human Services Contract
• Sep 11, 2026Procurement noticeRequest for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Some keyword matches were judged unrelated to this theme and are excluded from the record above.

How this story evolved

• Sep 14, 2026, 5:15 AM ETreal45 recordslatest record Sep 11, 2026

  HHS commits over $1.7B to smallpox countermeasures and Ebola vaccine, while DoD seeks medical countermeasure integration.

  The US government is significantly investing in biodefense and pandemic preparedness, with a strong focus on medical countermeasures. This effort is primarily driven by the Department of Health and Human Services (HHS) and the Department of Defense (DoD), who are issuing substantial contracts and solicitations for vaccines, antivirals, and integration services. The activity suggests a proactive stance on biological threats, building on existing frameworks and expanding capabilities.

• Sep 13, 2026, 5:15 AM ETreal45 recordslatest record Sep 11, 2026

  HHS commits over $1.7B to smallpox countermeasures and Ebola vaccine, while DoD seeks medical countermeasure integration.

  The US government is significantly investing in biodefense and pandemic preparedness, with a strong focus on medical countermeasures. This effort is primarily driven by the Department of Health and Human Services (HHS) and the Department of Defense (DoD), who are issuing substantial contracts and solicitations for vaccines, antivirals, and integration services. The activity suggests a proactive stance on biological threats, building on existing frameworks and expanding capabilities.

• Sep 12, 2026, 5:15 AM ETreal45 recordslatest record Sep 11, 2026

  HHS commits over $1.7B to smallpox countermeasures and Ebola vaccine, while DoD seeks medical countermeasure integration.

  The US government is significantly investing in biodefense and pandemic preparedness, with a strong focus on medical countermeasures. This effort is primarily driven by the Department of Health and Human Services (HHS) and the Department of Defense (DoD), who are issuing substantial contracts and solicitations for vaccines, antivirals, and integration services. The activity suggests a proactive stance on biological threats, building on existing frameworks and expanding capabilities.

• Sep 11, 2026, 5:15 AM ETreal41 recordslatest record Sep 8, 2026

  HHS commits over $1.7B to smallpox countermeasures and launches broad R&D for next-gen biodefense platforms.

  The US government is significantly ramping up its biodefense and pandemic preparedness efforts, with a strong focus on medical countermeasures. This push is led by the Department of Health and Human Services (HHS), particularly BARDA, which has committed over $1.7 billion to smallpox vaccines and antivirals. Concurrently, multiple agencies are soliciting and funding advanced R&D for next-generation platforms to combat emerging infectious diseases and drug-resistant threats.

• Sep 10, 2026, 5:15 AM ETreal41 recordslatest record Sep 8, 2026

  HHS commits $1.75B to smallpox countermeasures and launches multiple R&D initiatives for pandemic preparedness.

  The US government is significantly ramping up its biodefense and pandemic preparedness efforts, with a strong focus on medical countermeasures. This push is led by the Department of Health and Human Services (HHS), particularly BARDA, which has committed over $1.75 billion to smallpox vaccines and antivirals. Concurrently, multiple solicitations indicate a broader strategy to develop next-generation defenses against emerging infectious diseases and drug-resistant threats.

• Sep 9, 2026, 5:15 AM ETreal41 recordslatest record Sep 3, 2026

  HHS BARDA commits over $1.7B to smallpox countermeasures and R&D, signaling renewed biodefense focus.

  The US government is significantly increasing its investment in biodefense and pandemic preparedness, with a particular emphasis on medical countermeasures. This effort is primarily driven by the Department of Health and Human Services (HHS), specifically BARDA (Biomedical Advanced Research and Development Authority), which is allocating substantial funds to vaccine procurement and advanced research. The activity suggests a strategic pivot towards bolstering national readiness against biological threats, including smallpox and emerging infectious diseases.

• Sep 8, 2026, 5:15 AM ETreal42 recordslatest record Sep 3, 2026

  HHS BARDA commits over $1.7B to smallpox countermeasures and R&D, signaling renewed biodefense focus.

  The US government is significantly increasing its investment in biodefense and pandemic preparedness, with a particular emphasis on medical countermeasures. This effort is primarily driven by the Department of Health and Human Services (HHS), specifically BARDA (Biomedical Advanced Research and Development Authority), which is allocating substantial funds to vaccine procurement and advanced research. The activity suggests a strategic pivot towards bolstering national readiness against biological threats, including smallpox and emerging infectious diseases.

• Sep 7, 2026, 5:15 AM ETreal42 recordslatest record Sep 3, 2026

  HHS BARDA commits over $1.7B to smallpox countermeasures and R&D, signaling renewed biodefense focus.

  The US government is significantly increasing its investment in biodefense and pandemic preparedness, with a particular emphasis on medical countermeasures. This effort is primarily driven by the Department of Health and Human Services (HHS), specifically BARDA (Biomedical Advanced Research and Development Authority), which is allocating substantial funds to vaccine procurement and advanced research. The activity suggests a strategic pivot towards bolstering national readiness against biological threats, including smallpox and emerging infectious diseases.

• Sep 6, 2026, 5:15 AM ETreal42 recordslatest record Sep 3, 2026

  HHS BARDA commits over $1.7B to smallpox countermeasures and R&D, signaling renewed biodefense focus.

  The US government is significantly increasing its investment in biodefense and pandemic preparedness, with a particular emphasis on medical countermeasures. This effort is primarily driven by the Department of Health and Human Services (HHS), specifically BARDA (Biomedical Advanced Research and Development Authority), which is allocating substantial funds to vaccine procurement and advanced research. The activity suggests a strategic pivot towards bolstering national readiness against biological threats, including smallpox and emerging infectious diseases.

• Sep 5, 2026, 5:15 AM ETreal40 recordslatest record Sep 2, 2026

  HHS and DoD accelerate biodefense procurement, focusing on medical countermeasures and pandemic preparedness.

  The US government is significantly ramping up its biodefense and pandemic preparedness efforts, with a clear focus on stockpiling medical countermeasures and enhancing response capabilities. This initiative is primarily driven by the Department of Health and Human Services (HHS) and the Department of Defense (DoD), evidenced by substantial contracts and numerous procurement notices. The activity suggests a strategic shift towards proactive readiness against biological threats and future pandemics.

• Sep 4, 2026, 5:15 AM ETreal40 recordslatest record Aug 31, 2026

  HHS and DoD accelerate biodefense procurement, focusing on medical countermeasures and pandemic preparedness.

  The US government is significantly ramping up its biodefense and pandemic preparedness efforts, with a strong focus on medical countermeasures. This push is primarily driven by the Department of Health and Human Services (HHS) and the Department of Defense (DoD), evidenced by substantial contract awards and numerous solicitations. The activity suggests a strategic stockpiling and development of critical medical supplies and vaccines.

• Sep 3, 2026, 5:15 AM ETreal40 recordslatest record Aug 31, 2026

  HHS and DoD accelerate biodefense procurement, focusing on medical countermeasures and pandemic preparedness.

  The US government is significantly ramping up its biodefense and pandemic preparedness efforts, with a strong focus on medical countermeasures. This push is primarily driven by the Department of Health and Human Services (HHS) and the Department of Defense (DoD), evidenced by substantial contract awards and numerous solicitations. The activity suggests a strategic stockpiling and development of critical medical supplies and vaccines.